6.
Sun Y
. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2003; 2(6):623-9.
View
7.
Gan S, Tan E, Lin X, Yu D, Wang J, Tan G
. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem. 2012; 287(29):24671-89.
PMC: 3397895.
DOI: 10.1074/jbc.M111.332791.
View
8.
Bartee E, Mansouri M, Nerenberg B, Gouveia K, Fruh K
. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004; 78(3):1109-20.
PMC: 321412.
DOI: 10.1128/jvi.78.3.1109-1120.2004.
View
9.
Tada T, Zhang Y, Koyama T, Tobiume M, Tsunetsugu-Yokota Y, Yamaoka S
. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med. 2015; 21(12):1502-7.
DOI: 10.1038/nm.3956.
View
10.
Bukreyev A, Whitehead S, Murphy B, Collins P
. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol. 1997; 71(12):8973-82.
PMC: 230197.
DOI: 10.1128/JVI.71.12.8973-8982.1997.
View
11.
Peng R, Chen C, Chen Q, Zhang Y, Huang R, Zhang Y
. Global progress in clinical research on human respiratory syncytial virus vaccines. Front Microbiol. 2024; 15:1457703.
PMC: 11402711.
DOI: 10.3389/fmicb.2024.1457703.
View
12.
Li Y, Jain N, Limpanawat S, To J, Quistgaard E, Nordlund P
. Interaction between human BAP31 and respiratory syncytial virus small hydrophobic (SH) protein. Virology. 2015; 482:105-10.
DOI: 10.1016/j.virol.2015.03.034.
View
13.
Taleb S, Al Thani A, Al Ansari K, Yassine H
. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis. 2018; 37(10):1817-1827.
DOI: 10.1007/s10096-018-3289-4.
View
14.
Samji T, Hong S, Means R
. The Membrane Associated RING-CH Proteins: A Family of E3 Ligases with Diverse Roles through the Cell. Int Sch Res Notices. 2016; 2014:637295.
PMC: 4897099.
DOI: 10.1155/2014/637295.
View
15.
Liu X, Xu F, Ren L, Zhao F, Huang Y, Wei L
. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Nat Commun. 2021; 12(1):4427.
PMC: 8292393.
DOI: 10.1038/s41467-021-24724-2.
View
16.
Blanken M, Rovers M, Molenaar J, Winkler-Seinstra P, Meijer A, Kimpen J
. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368(19):1791-9.
DOI: 10.1056/NEJMoa1211917.
View
17.
Lehner P, Hoer S, Dodd R, Duncan L
. Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases. Immunol Rev. 2005; 207:112-25.
DOI: 10.1111/j.0105-2896.2005.00314.x.
View
18.
Yu C, Li S, Zhang X, Khan I, Ahmad I, Zhou Y
. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation. mBio. 2020; 11(5).
PMC: 7492737.
DOI: 10.1128/mBio.01882-20.
View
19.
Zhao Y, Sui L, Wu P, Li L, Liu L, Ma B
. EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus replication through the E3 ubiquitin ligase MARCH8. J Virol. 2023; 97(10):e0102823.
PMC: 10653994.
DOI: 10.1128/jvi.01028-23.
View
20.
Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C
. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064.
PMC: 7613574.
DOI: 10.1016/S0140-6736(22)00478-0.
View